Sartorius Stedim Biotech SA (SSB), a subsidiary of Sartorius AG, provides equipment and services to the pharmaceutical and biotechnology industries. It assists customers in developing production processes and manufacturing biotech medications and vaccines more efficiently. The company operates worldwide and has subsidiaries in more than 30 countries. Its products are used in various applications such as life science research, biopharmaceutical manufacturing, food and beverage, environmental, and medical devices. SSB offers a broad portfolio of products and services that cover all major steps in the manufacture of biopharmaceuticals and process development. This includes cell line technologies, cell culture media, bioreactors, and a variety of technologies for the separation, purification, and concentration of biological intermediates and finished products. The company also provides solutions for storage and transportation, as well as data analysis software for modeling and optimizing biopharmaceutical development and production processes. Its products are used in the manufacture of various biological drug classes, such as monoclonal antibodies, vaccines, antibody drug conjugates, and cell and gene therapies. SSB operates around 30 manufacturing sites across the EMEA, Americas, and Asia-Pacific regions.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

SSB's R&D arm focuses on making the development and production of biotech medicines safer and more efficient by covering the entire value-added chain of the biopharmaceutical industry. The company aims to ensure that novel therapies and vaccines reach the market faster and are accessible to more people worldwide. SSB Corporate Research drives cross-divisional research and development, analyzing new trends, tools, and features to assess their relevance for customers and patients. The R&D unit of the company is Sartorius Corporate Research. This unit is responsible for driving cross-divisional research and development with a focus on long-term technological advancements. It works in close cooperation with companies, research institutes, and start-ups to identify relevant developments early on, enabling the company to move into future areas of research and business. The company operates R&D sites in Europe, North America, and Asia. As of December 2025, the company had 1,067 employees in its R&D department and filed a total of 218 applications for intellectual property rights; it was granted 374 patents and trademarks; and its portfolio consisted of 5,660 patents and trademarks. In FY2025, the company spent EUR133.1 million on its R&D activities, which as a percentage of revenue stood at 4.5% and grew 7.6% YoY.